(5,11-Dimethyl-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraen-16-yl)-pyridin-3-ylmethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - Pyrroloazepines
• 英文名称: (5,11-Dimethyl-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraen-16-yl)-pyridin-3-ylmethanol
• 英文别名: (5,11-dimethyl-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraen-16-yl)-pyridin-3-ylmethanol
• 化学式: C₂₃H₂₇N₃O
• 分子量: 361.5
• InChiKey: VKNRYYGCBKDHJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  41.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20140228353A1

  公开（公告）日：2014-08-14

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α 2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  介绍了氢化吡咯[4,3-b]吲哚、吡咯[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素α2A受体。这些化合物也可以结合并拮抗肾上腺素α2B受体；或者这些化合物不是肾上腺素α2B受体的拮抗剂，并且这些化合物与第二种预计可以降低血压的药物一起使用。这些化合物可以用于治疗，例如调节血糖水平，增加胰岛素分泌并治疗对胰岛素产生增加反应的疾病或状况。特别描述了使用这些化合物治疗2型糖尿病的方法。
• US9434747B2
  申请人：——

  公开号：US9434747B2

  公开（公告）日：2016-09-06